Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)

CNY 18.41

(-1.13%)

Operating Expenses Summary of Zhejiang Wecome Pharmaceutical Company Limited

Zhejiang Wecome Pharmaceutical Company Limited's latest annual operating expenses in 2023 was 262.87 Million CNY , up 13.62% from previous year.
Zhejiang Wecome Pharmaceutical Company Limited's latest quarterly operating expenses in 2024 Q2 was 61.62 Million CNY , down -10.2% from previous quarter.
Zhejiang Wecome Pharmaceutical Company Limited reported a annual operating expenses of 250.36 Million CNY in annual operating expenses 2022, down -22.8% from previous year.
Zhejiang Wecome Pharmaceutical Company Limited reported a annual operating expenses of 324.3 Million CNY in annual operating expenses 2021, up 12.02% from previous year.
Zhejiang Wecome Pharmaceutical Company Limited reported a quarterly operating expenses of 75.14 Million CNY for 2024 Q3, down -119.23% from previous quarter.
Zhejiang Wecome Pharmaceutical Company Limited reported a quarterly operating expenses of 68.62 Million CNY for 2024 Q1, down -41.01% from previous quarter.

Annual Operating Expenses Chart of Zhejiang Wecome Pharmaceutical Company Limited (2023 - 2013)

Historical Annual Operating Expenses of Zhejiang Wecome Pharmaceutical Company Limited (2023 - 2013)

Year	Operating Expenses	Operating Expenses Growth
2023	262.87 Million CNY	13.62%
2022	250.36 Million CNY	-22.8%
2021	324.3 Million CNY	12.02%
2020	289.5 Million CNY	-10.51%
2019	323.5 Million CNY	-0.96%
2018	326.63 Million CNY	88.24%
2017	173.52 Million CNY	86.65%
2016	92.97 Million CNY	41.64%
2015	65.63 Million CNY	36.28%
2014	48.16 Million CNY	20.43%
2013	39.99 Million CNY	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	61.62 Million CNY	-10.2%
2024 Q3	75.14 Million CNY	-119.23%
2024 Q1	68.62 Million CNY	-41.01%
2023 Q2	60.19 Million CNY	6.72%
2023 Q1	56.4 Million CNY	-7.82%
2023 FY	284.45 Million CNY	13.62%
2023 Q4	116.33 Million CNY	125.81%
2023 Q3	51.52 Million CNY	-14.41%
2022 Q4	61.18 Million CNY	-15.2%
2022 Q3	72.15 Million CNY	65.88%
2022 Q2	43.5 Million CNY	-40.83%
2022 Q1	73.52 Million CNY	1.95%
2022 FY	250.36 Million CNY	-22.8%
2021 Q4	72.11 Million CNY	-24.18%
2021 Q1	63.33 Million CNY	13.47%
2021 FY	324.3 Million CNY	12.02%
2021 Q2	93.73 Million CNY	48.01%
2021 Q3	95.11 Million CNY	1.47%
2020 Q2	82.48 Million CNY	19.83%
2020 Q1	68.84 Million CNY	-20.61%
2020 Q3	82.35 Million CNY	-0.16%
2020 Q4	55.81 Million CNY	-32.23%
2020 FY	289.5 Million CNY	-10.51%
2019 Q4	86.7 Million CNY	2.4%
2019 FY	323.5 Million CNY	-0.96%
2019 Q3	84.67 Million CNY	9.9%
2019 Q2	77.04 Million CNY	0.0%
2019 Q1	77.04 Million CNY	0.0%
2018 FY	326.63 Million CNY	88.24%
2017 FY	173.52 Million CNY	86.65%
2016 FY	92.97 Million CNY	41.64%
2015 FY	65.63 Million CNY	36.28%
2014 FY	48.16 Million CNY	20.43%
2013 FY	39.99 Million CNY	0.0%

Peer Operating Expenses Comparison of Zhejiang Wecome Pharmaceutical Company Limited

Name	Operating Expenses	Operating Expenses Difference
Lifecome Biochemistry Co.,Ltd.	190.7 Million CNY	-37.842%
Chengdu Kanghua Biological Products Co., Ltd.	898.63 Million CNY	70.748%
NanHua Bio-medicine Co., Ltd	137.65 Million CNY	-90.958%
Shandong Sito Bio-technology Co., Ltd.	235.57 Million CNY	-11.587%
Porton Pharma Solutions Ltd.	1.16 Billion CNY	77.498%
Guangdong VTR Bio-Tech Co., Ltd.	331.11 Million CNY	20.611%